Business Overview: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

---

Executive Summary

Ligand Pharmaceuticals Incorporated describes itself as a "biopharmaceutical royalty aggregator." Rather than discovering and commercializing its own drugs, Ligand funds mid- to late-stage biopharmaceutical programs in exchange for royalty and economic rights, acquires royalties on already-developing or commercial products, and licenses two proprietary platform technologies — Captisol, a solubility and stability enhancer, and NITRICIL, a tunable-dosing nitric oxide platform. Headquartered in San Diego, California, Ligand has built a portfolio of royalty interests across more than a dozen commercial-stage products and over 75 earlier-stage programs.

Ligand matters in the specialty pharma/royalty space as one of the few publicly traded "royalty aggregators," a business model that lets investors gain diversified exposure to biopharma commercial success without taking on single-drug clinical or commercialization risk. The company generated $167.1 million of total revenue in 2024 (up from $131.3 million in 2023) and ended the year with $256.2 million in cash, equivalents, and short-term investments. In April 2026, Ligand announced a transformative $739 million acquisition of fellow royalty aggregator XOMA Royalty, a deal management says will nearly double Ligand's royalty portfolio and lift 2026 revenue guidance to $270-310 million.

---

1. Core Business Model & How They Work

  Capital Deployment        -->   Royalty / Milestone       -->   Revenue
  (fund Phase 3-stage             Rights Acquired                  - Royalties on
  programs, buy existing          (on partner drugs)                 commercial products
  royalty streams, license                                         - Captisol material sales
  Captisol/NITRICIL)                                                - License fees & milestones

Ligand earns revenue through three channels: royalties from commercialized partner products, Captisol material sales to pharmaceutical partners who use it in their formulations, and contract revenue from license fees and milestone payments as partner programs advance. Its strategy specifically targets Phase 3-stage assets within a few years of approval and with strong market exclusivity, aiming to capture upside as programs move toward and through commercialization without funding the earlier, higher-risk stages of drug development itself. The model is deliberately "infrastructure-light" — Ligand does not build its own sales force or manufacturing plants for partnered drugs; partners commercialize the products while Ligand collects a royalty or milestone stream.

---

3. Product Portfolio (Platform Technologies & Royalty Assets)

---

4. Competitive Landscape

Ligand's primary competitive dynamic is less about rival drugs and more about rival capital providers competing to fund or acquire biopharma royalty streams:

• Royalty Pharma — the dominant, much larger player in the royalty-aggregator space, competing for the same late-stage royalty-acquisition deals.
• XOMA Royalty — a direct peer royalty aggregator that Ligand itself agreed to acquire for roughly $739 million in April 2026, consolidating two aggregators into one larger combined portfolio.
• Other specialty royalty/financing players (e.g., DRI Healthcare Trust and similar royalty funds) — compete to acquire royalty interests on commercial or near-commercial drugs.
• Captisol-specific competition — other cyclodextrin suppliers and alternative solubility-enhancing technologies compete for formulation partners' business.

Ligand's relative positioning after the XOMA deal is as a larger, more diversified royalty aggregator, management-light and able to absorb XOMA's 120+ additional royalty assets with minimal incremental operating cost given Ligand's existing portfolio-management infrastructure.

---

5. Strategic Strengths & Risks

Strengths (moat sources):

• Diversified royalty portfolio across 12+ commercial-stage assets and 75+ earlier-stage programs, meaning no single drug's failure threatens the whole business.
• Captisol and NITRICIL platform technologies generate both licensing/material-sales revenue and ongoing royalty-generating optionality from new formulations built on them.
• Deal-sourcing and portfolio-management expertise demonstrated by the pending XOMA Royalty acquisition, which management says can be absorbed with almost no added operating cost — a scale advantage in royalty aggregation itself.

Risks:

• Reliance on third-party commercialization — Ligand does not control partner companies' sales execution, regulatory outcomes, or pricing, so royalty revenue depends entirely on partners' success.
• Revenue and earnings volatility — 2024 GAAP net loss ($4.0 million) versus 2023 net income ($52.2 million) shows how one-time items (e.g., equity gains/losses on holdings like Viking Therapeutics) can swing reported results significantly.
• Integration risk from the XOMA acquisition — absorbing 120+ new royalty/milestone assets, including Xoma's pending Tremfya-related litigation CVR obligations, adds complexity even if accretive.
• Captisol/platform competition — alternative solubility technologies could erode Captisol's commercial relevance over time.

---

6. Financial Overview

---

7. Summary Conclusion

Ligand's moat comes from its diversified, infrastructure-light royalty-aggregator model: by funding or acquiring royalty streams across a dozen-plus commercial drugs and dozens of earlier-stage programs, it captures upside from biopharma innovation without bearing the cost or risk of running its own commercial organization. The pending $739 million acquisition of XOMA Royalty extends that model's core advantage — the ability to absorb large new royalty portfolios with minimal added operating cost — and is expected to nearly double Ligand's revenue base. The biggest forward risk is less about any single drug and more about execution and integration risk from rapidly scaling the portfolio, combined with Ligand's structural dependence on partner companies' continued commercial success for the royalty income the entire business model is built on.